PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
121.05%
Positive EBIT growth while CRVO is negative. John Neff might see a substantial edge in operational management.
-6.92%
Both companies face negative operating income growth. Martin Whitman would suspect broader market or cost hurdles.
121.05%
Positive net income growth while CRVO is negative. John Neff might see a big relative performance advantage.
121.15%
Positive EPS growth while CRVO is negative. John Neff might see a significant comparative advantage in per-share earnings dynamics.
115.11%
Positive diluted EPS growth while CRVO is negative. John Neff might view this as a strong relative advantage in controlling dilution.
2.25%
Share reduction more than 1.5x CRVO's 48.25%. David Dodd would see if the company is taking advantage of undervaluation to retire shares.
42.15%
Diluted share count expanding well above CRVO's 48.25%. Michael Burry would fear significant dilution to existing owners' stakes.
No Data
No Data available this quarter, please select a different quarter.
-3.22%
Both companies show negative OCF growth. Martin Whitman would analyze broader economic or industry conditions limiting cash flow.
-8.23%
Both companies show negative FCF growth. Martin Whitman would consider an industry-wide capital spending surge or margin compression.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-39049.73%
Negative 10Y OCF/share CAGR while CRVO stands at 0.00%. Joel Greenblatt would scrutinize managerial effectiveness and product competitiveness.
-717224.10%
Negative 5Y OCF/share CAGR while CRVO is at 50.45%. Joel Greenblatt would question the firm’s operational model or cost structure.
-12351.82%
Negative 3Y OCF/share CAGR while CRVO stands at 92.72%. Joel Greenblatt would demand an urgent turnaround in the firm’s cost or revenue drivers.
45138.86%
10Y net income/share CAGR of 45138.86% while CRVO is zero. Bruce Berkowitz would see if minor gains can compound into a bigger lead over time.
41496.01%
5Y net income/share CAGR above 1.5x CRVO's 72.54%. David Dodd would confirm if the firm’s strategy is more effective in generating mid-term profits.
7331.25%
3Y net income/share CAGR above 1.5x CRVO's 87.83%. David Dodd would confirm the company’s short-term strategies outmatch the competitor significantly.
8529.17%
Equity/share CAGR of 8529.17% while CRVO is zero. Bruce Berkowitz might see a slight advantage that can compound significantly over 10 years.
2357.47%
5Y equity/share CAGR above 1.5x CRVO's 313.13%. David Dodd might see stronger earnings retention or fewer asset impairments fueling growth.
2495.43%
Positive short-term equity growth while CRVO is negative. John Neff sees a strong advantage in near-term net worth buildup.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
135.47%
Asset growth 1.25-1.5x CRVO's 106.18%. Bruce Berkowitz sees if the firm's investments effectively outpace the competitor in future returns.
131.44%
75-90% of CRVO's 150.15%. Bill Ackman advocates improvements in profitability or buybacks to keep pace in net worth growth.
-41.82%
Both reduce debt yoy. Martin Whitman sees a broader sector shift to safer balance sheets or less growth impetus.
-18.65%
Our R&D shrinks while CRVO invests at 57.62%. Joel Greenblatt checks if we risk falling behind a competitor’s new product pipeline.
44.07%
SG&A growth well above CRVO's 19.78%. Michael Burry sees potential margin erosion unless it translates into higher sales or brand equity.